


Blonanserin dihydrochloride

Cat. No.:	HY-13575A
CAS No.:	132812-45-4
Molecular Formula:	C ₂₃ H ₃₂ Cl ₂ FN ₃
Molecular Weight:	440.42
Target:	5-HT Receptor; Dopamine Receptor; Adrenergic Receptor; Sigma Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Blonanserin dihydrochloride is a potent and orally active 5-HT _{2A} and dopamine D ₂ receptor antagonist, with K _i values of 0.812 and 0.142 nM, respectively. Blonanserin dihydrochloride usually acts as an atypical antipsychotic agent, and can be used for the research of extrapyramidal symptoms, excessive sedation, or hypotension ^{[1][2]} .			
IC₅₀ & Target	D ₂ Receptor 0.142 nM (K _i)	D ₃ Receptor 0.494 nM (K _i)	D ₄ Receptor 150 nM (K _i)	D ₁ Receptor 1070 nM (K _i)
	5-HT _{2A} Receptor 0.812 nM (K _i)	5-HT _{2C} Receptor 26.4 nM (K _i)	5-HT ₆ Receptor 11.7 nM (K _i)	α ₁ -adrenergic receptor 26.7 nM (K _i)
	α ₂ -adrenergic receptor 530 nM (K _i)			
In Vitro	Blonanserin dihydrochloride exerts some blockade of α ₁ -adrenergic receptors (K _i =26.7 nM) and also shows significant affinity for the D ₃ receptor (K _i =0.494 nM). Blonanserin dihydrochloride possesses low affinity for the sigma receptor (IC ₅₀ =286 nM), but lacks significant affinity for numerous other sites including the 5-HT _{1A} , 5-HT ₃ , D ₁ , α ₂ -adrenergic, β-adrenergic, H ₁ , and mACh receptors and the monoamine transporters ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
In Vivo	Blonanserin dihydrochloride (Oral gavage; 1 mg/kg; once a day for 14 days) significantly ameliorates the social deficit observed in PCP-administered mice and inhibits the decrease in the levels of Ser897-phosphorylation, but pretreatment with blonanserin does not affect the social behaviors in saline-administered mice ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
	Animal Model:	Mice received saline or phencyclidine once a day for 14 consecutive days ^[2]		
	Dosage:	1 mg/kg		
	Administration:	Oral gavage; once a day for 14 days		
	Result:	Had an effect on the social deficit in mice that received repeated PCP administration.		

REFERENCES

[1]. Blonanserin

[2]. Saori Takeuchi, et al. Blonanserin ameliorates social deficit through dopamine-D₃ receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia. *Neurochem Int.* 2019 Sep;128:127-134.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA